期刊
OBSTETRICS AND GYNECOLOGY
卷 119, 期 2, 页码 423-426出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AOG.0b013e318234d97c
关键词
-
资金
- NCI NIH HHS [P50 CA098258-01, P30 CA016672] Funding Source: Medline
BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility. (Obstet Gynecol 2012;119:423-6) DOI:10.1097/AOG.0b013e318234d97c
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据